Abstract
Purpose :
Choroidal lymphomas are a rare ocular tumor. The optimal treatment for these rare tumors are unknown. We performed a multi-centered epidemiological study to compare outcomes of different treatment modalities.
Methods :
Data of patients with choroidal lymphomas were isolated from the Surveillance, Epidemiology, and End Results (SEER) database from 1998 to 2018. Univariate and multivariate logistic regressions were used to analyze predictors of non-Hodgkin’s lymphoma (NHL) specific survival and overall survival. Variables analyzed included age, sex, race, surgery, radiation, and chemotherapy.
Results :
36 patients were found to have choroidal lymphomas. The study group included 18 males and 18 females with a mean age of 65.1-years-old (SD = 12.8). Of these patients, 29 were non-Hispanic white (81%), five were Hispanic (14%), and one was non-Hispanic Black (3%). In this cohort, a total of 13 patients died within the study period (36.1%), five of whom died of NHL (38.4%). Nine (25.0%) were treated with chemotherapy, 19 with beam radiation (52.8%), and 5 (13.9%) with surgery. Of the patients who underwent surgery, one (20%) received laser ablation , two (40%) received a partial removal of the primary site , and two (40%) received a total surgical removal of primary site, which may include enucleation. Univariate logistic regression analysis showed chemotherapy (OR 0.048, 95% CI 0.0022-0.4049, p = 0.013) to be a negative predictor of NHL-specific survival, but not a significant predictor of overall survival. Among age, sex, race, surgery, and radiation, no positive predictors of either NHL survival or overall survival were found (p > 0.05). <div> </div>
Conclusions :
To our knowledge this is the first study to show that chemotherapy was a negative predictor of survival in non hodgkin's choroidal lymphomas. Radiation did not increase survival in patients as well. However, larger prospective studies will be needed to determine the optimal treatment modality.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.